Showing 478 news articles about New & experimental hepatitis C treatment

Filters Content type: Editors' picks Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

Editor's pick
Gilead press release
10 October 2014
New & experimental hepatitis C treatment

In a surprise move, Bristol-Myers drops U.S. approval plans for hep C drug

Editor's pick
Fierce Biotech
7 October 2014
Pharmaceutical industry

J&J makes a splash in hep C with a $1.75B deal for Alios

Editor's pick
Fierce Biotech
1 October 2014
New & experimental hepatitis C treatment

After Patient's Death, Study Shows HCV Drug Cardiotoxic in 14 of 34 Treated Patients

Editor's pick
Medscape (requires registration)
29 September 2014
New & experimental hepatitis C treatment

Patent landscape for hepatitis issued by WHO

Editor's pick
Intellectual Property Watch
29 September 2014
New & experimental hepatitis C treatment

European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults

Editor's pick
Gilead press release
29 September 2014
New & experimental hepatitis C treatment

AbbVie 3D hepatitis C regimen is well-tolerated in Phase 3 trials

Editor's pick
HIVandHepatitis.com
15 September 2014
Pharmaceutical industry

Gilead to raise price for new hepatitis C drug above $84000

Editor's pick
Reuters
15 September 2014
Hepatitis C treatment

MSF urges BMS to make daclatasvir accessible in low-and middle-income countries

Editor's pick
Pharmabiz
1 September 2014
New & experimental hepatitis C treatment

European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection

Editor's pick
Bristol-Myers Squibb
27 August 2014
New & experimental hepatitis C treatment

PegLambda discontinued by BMS

Editor's pick
EATG
18 August 2014
New & experimental hepatitis C treatment

Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

Editor's pick
Achillion press release
18 August 2014
Hepatitis C treatment

HIV, HCV and TB Pipeline Report

Editor's pick
Treatment Action Group & i-Base
21 July 2014
Hepatitis C treatment

EU nations join forces against 'exorbitant' hepatitis C drug: France

Editor's pick
Medical Xpress
10 July 2014
New & experimental hepatitis C treatment

Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen

Editor's pick
Bristol-Myers Squibb press release
8 July 2014
New & experimental hepatitis C treatment

Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza® (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union

Editor's pick
Bristol-Myers Squibb press release
30 June 2014
New & experimental hepatitis C treatment

HCV drug out of the running

Editor's pick
MedPage Today
23 June 2014
New & experimental hepatitis C treatment

A 4-week hep C cure? Bristol to test drugs with Gilead's Sovaldi

Editor's pick
Reuters
23 June 2014
New & experimental hepatitis C treatment

UNITED STATES: FDA Approves AbbVie's Hepatitis C Regimen for Priority Review

Editor's pick
CDC
19 June 2014
New & experimental hepatitis C treatment

AbbVie all-oral hepatitis C therapy gets rapid EU review

Editor's pick
Reuters
17 June 2014
New & experimental hepatitis C treatment

NICE consults on draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C

Editor's pick
NICE press release
16 June 2014
New & experimental hepatitis C treatment

Why Merck Just Spent $4 Billion On New Drugs For Hepatitis C

Editor's pick
Forbes
9 June 2014
New & experimental hepatitis C treatment

No critical interactions between ledipasvirsofosbuvir and certain key antiretrovirals

Editor's pick
NATAP
29 May 2014
New & experimental hepatitis C treatment

OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection

Editor's pick
Reuters
16 May 2014